ISBN: 978-1-4731-3093-7 Chapter Type of review Review questions Outcomes Exercise capacity Adverse events (withdrawal from the exercise programme) Adherence (including maintenance of exercise/physical activity) Health service use 8 Intervention What is the clinical and cost effectiveness of biomarker-based monitoring, monitoring with cardiac MRI, and monitoring with repeated echocardiography in people with heart failure? Critical outcomes: Mortality (Time to event) Quality of life at 12 months (Continuous) Unplanned hospitalisation (all- cause) (Count rate) Important outcomes: Adverse events - hypotension (Dichotomous) Adverse events - hyperkalaemia (Dichotomous) Adverse events - renal function (Continuous) Adverse events - bradycardia (Dichotomous) Adverse events - arrhythmic events (Dichotomous) 8 Intervention What is the clinical and cost effectiveness of biomarker-based monitoring, monitoring with cardiac MRI, and monitoring with repeated echocardiography in people with heart failure who also have CKD? Critical outcomes: Mortality (Time to event) Quality of life at 12 months (Continuous) Unplanned hospitalisation (all- cause) (Count rate) Important outcomes: Adverse events - hypotension (Dichotomous) Adverse events - hyperkalaemia (Dichotomous) Adverse events - renal function (Continuous) Adverse events - bradycardia (Dichotomous) Adverse events - arrhythmic events (Dichotomous) 8 Intervention What is the clinical and cost effectiveness of biomarker-based monitoring, monitoring with cardiac MRI, and monitoring with repeated echocardiography in people with heart failure who also have atrial fibrillation? Critical outcomes: Mortality at during study (Time to event) Quality of life at 12 months (Continuous) Unplanned hospitalisation (all- cause) (Count rate) Important outcomes: Adverse events - hypotension Chronic Heart Failure Methods NICE 2018. All rights reserved. Subject to Notice of rights. 